Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Top Cited Papers
Open Access
- 8 December 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (23) , 2450-2461
- https://doi.org/10.1056/nejmoa050373
Abstract
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.Keywords
This publication has 31 references indexed in Scilit:
- A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapyArthritis Care & Research, 2004
- Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Care & Research, 2002
- Gout and hyperuricemiaCurrent Opinion in Rheumatology, 2002
- Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic goutAnnals of the Rheumatic Diseases, 1998
- A structural approach to pathological crystallizations. Gout: the possible role of albumin in sodium urate crystallizationProceedings of the Royal Society of London. B. Biological Sciences, 1988
- Studies of urate crystallisation in relation to gout.Annals of the Rheumatic Diseases, 1983
- Studies on the nucleation of monsodium urate at 37°CArthritis & Rheumatism, 1980
- Solubility of uric acid and monosodium urateMedical & Biological Engineering & Computing, 1972
- The influence of temperature on the solubility of monosodium urateArthritis & Rheumatism, 1972
- Inhibition of monosodium urate needle crystal growthArthritis & Rheumatism, 1965